Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
Status:
Not yet recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
This randomized placebo-controlled clinical trial will evaluate the effect of
sacubitril/valsartan (compared with placebo) on echocardiographic measures of hypervolemia,
preservation of residual renal function, and key safety parameters in incident hemodialysis
patients.
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Sacubitril and valsartan sodium hydrate drug combination Valsartan